GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Johnson & Johnson (BUE:JNJ) » Definitions » Short Ratio

Johnson & Johnson (BUE:JNJ) Short Ratio


View and export this data going back to . Start your Free Trial

What is Johnson & Johnson Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.


Johnson & Johnson (BUE:JNJ) Business Description

Address
One Johnson and Johnson Plaza, New Brunswick, NJ, USA, 08933
Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.

Johnson & Johnson (BUE:JNJ) Headlines

From GuruFocus

Q3 2023 Johnson & Johnson Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q4 2022 Johnson & Johnson Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q1 2022 Johnson & Johnson Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q3 2022 Johnson & Johnson Earnings Call Transcript

By GuruFocus Research 01-23-2024

Johnson & Johnson Financials and Guidance Call Transcript

By GuruFocus Research 01-23-2024

Q2 2022 Johnson & Johnson Earnings Call Transcript

By GuruFocus Research 01-23-2024